FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)

Listen to an audio podcast of the June 30, 2022, FDA Drug Safety Communication. Results from a clinical trial show a possible increased risk of death with Copiktra (active ingredient duvelisib) compared to another medicine to treat leukemia and lymphoma.

Source: FDA Drug Safety Podcasts - July 27, 2022 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts